Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study

被引:181
作者
Chan, Esther W. [1 ]
Lau, Wallis C. Y. [1 ]
Leung, Wai K. [2 ]
Mok, Michael T. C. [3 ,4 ]
He, Ying [1 ]
Tong, Teresa S. M. [2 ]
Wong, Ian C. K. [1 ]
机构
[1] Univ Hong Kong, Ctr Safe Medicat Practice & Res, Dept Pharmacol & Pharm, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Hong Kong, Peoples R China
[3] Geelong Hosp, Dept Cardiol, Geelong, Vic, Australia
[4] Deakin Univ, Geelong, Vic 3217, Australia
关键词
Anticoagulant; Drug Side Effect; PPI; H2RA; ORAL ANTICOAGULANTS; ATRIAL-FIBRILLATION; PEPTIC-ULCER; WARFARIN; RISK; ASSOCIATION; PREVALENCE; ANTAGONIST; HEMORRHAGE; ETEXILATE;
D O I
10.1053/j.gastro.2015.05.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Use of dabigatran, an inhibitor of thrombin, increases the risk of gastrointestinal bleeding (GIB). However, it is not clear whether gastroprotective agents (GPAs) prevent GIB in dabigatran users. We investigated the risk of GIB and the role of gastroprotective agents (including proton pump inhibitors and histamine type-2-receptor antagonists) in patients using dabigatran. METHODS: We performed a retrospective cohort study using a population-wide database managed by the Hong Kong Hospital Authority. Patients newly prescribed dabigatran from 2010 through 2013 were included in the analysis. Poisson regression was used to assess the risk of GIB in dabigatran users by incidence rate ratio (IRR), adjusted for patient characteristics, comorbidities, and concurrent medications. RESULTS: Among the 5041 patients newly prescribed dabigatran, 124 (2.5%) developed GIB during follow-up evaluation (4.2/100 patient-years). The risk of GIB in this population increased among patients 75 years and older (IRR, 2.47; 95% confidence interval [CI], 1.66-3.68), patients with a history of peptic ulcers or GIB (IRR, 2.31; 95% CI, 1.54-3.46), and patients who used aspirin (IRR, 1.52; 95% CI, 1.03-2.24). Concomitant use of gastroprotective agents was associated with a reduced risk of GIB (IRR, 0.52; 95% CI, 0.35-0.77). Subcategory analysis showed that use of proton pump inhibitors (IRR, 0.53; 95% CI, 0.31-0.91) or histamine type-2-receptor antagonists (IRR, 0.61; 95% CI, 0.40-0.94) were associated with a lower risk of GIB. Further analysis showed that the risk reduction by gastroprotective agents was significant for only upper GIB (IRR, 0.29; 95% CI, 0.15-0.54), and only for patients with a prior history of peptic ulcers or GIB (IRR, 0.14; 95% CI, 0.06-0.30). CONCLUSIONS: In the Hong Kong population, use of gastroprotective agents was associated with a reduced risk of GIB in patients taking dabigatran. The association was stronger for upper GIB than lower GIB, and in patients with a prior history of peptic ulcers or GIB.
引用
收藏
页码:586 / +
页数:13
相关论文
共 58 条
[1]   ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents [J].
Abraham, Neena S. ;
Hlatky, Mark A. ;
Antman, Elliott M. ;
Bhatt, Deepak L. ;
Bjorkman, David J. ;
Clark, Craig B. ;
Furberg, Curt D. ;
Johnson, David A. ;
Kahi, Charles J. ;
Laine, Loren ;
Mahaffey, Kenneth W. ;
Quigley, Eamonn M. ;
Scheiman, James ;
Sperling, Laurence S. ;
Tomaselli, Gordon F. ;
Harrington, Robert A. ;
Bates, Eric R. ;
Bhatt, Deepak L. ;
Ferrari, Victor A. ;
Fisher, John D. ;
Gardner, Timothy J. ;
Gentile, Federico ;
Hlatky, Mark A. ;
Jacobs, Alice K. ;
Kaul, Sanjay ;
Moliterno, David J. ;
Weitz, Howard H. ;
Wesley, Deborah J. .
CIRCULATION, 2010, 122 (24) :2619-2633
[2]   Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy [J].
Agewall, Stefan ;
Cattaneo, M. ;
Collet, J. P. ;
Andreotti, F. ;
Lip, G. Y. H. ;
Verheugt, F. W. A. ;
Huber, K. ;
Grove, E. L. ;
Morais, J. ;
Husted, S. ;
Wassmann, S. ;
Rosano, G. ;
Atar, D. ;
Pathak, A. ;
Kjeldsen, K. ;
Storey, R. F. .
EUROPEAN HEART JOURNAL, 2013, 34 (23) :1708-+
[3]  
[Anonymous], Introduction
[4]  
[Anonymous], 2012, HLTH SERV DEL PROF
[5]  
Black N, 1996, BRIT MED J, V312, P1215
[6]  
Carter A, 2014, Ann R Coll Surg Engl, V96, p115E, DOI 10.1308/003588414X13824511649779
[7]  
Census and Statistics Department HKSAR, POP HOUS STAT AN DIS
[8]   Influenza-related hospitalizations among children in Hong Kong [J].
Chiu, SS ;
Lau, YL ;
Chan, KH ;
Wong, WHS ;
Peiris, JSM .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (26) :2097-2103
[9]   An investigation of the potential association between retinal detachment and oral fluoroquinolones: a self-controlled case series study [J].
Chui, Celine S. L. ;
Man, Kenneth K. C. ;
Cheng, Ching-Lan ;
Chan, Esther W. ;
Lau, Wallis C. Y. ;
Cheng, Vincent C. C. ;
Wong, David S. H. ;
Kao, Yea-Huei Yang ;
Wong, Ian C. K. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (09) :2563-2567
[10]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151